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Abstract 
 
Mesenchymal stem cell (MSC) injections for osteoarthritis is reviewed. 
Methods 
PubMed search was conducted to identify articles in English from 2003-2018 that used intra- 
articular injection (IA), cartilage repair, cartilage regeneration, chondral injury, adipose stem 
cells, bone marrow stem cells, mesenchymal stem cells, or autologous stem cells. 
Results  
388 patients receiving IA MSC injections are discussed with data obtained from 10 case reports 
or case series, 4 randomized clinical trials (RCT), 1 cohort study, and 3 case controlled 
therapeutic studies. 
Conclusions  
MSC injections may be an effective adjunct in the management of osteoarthritis and a variety of 
cartilage related pathologies. 
Keywords 
stem cells, osteoarthritis, review 
Introduction 
Osteoarthritis (OA) is a degenerative disease of diarthrodial joints characterized by loss of 
articular cartilage, deformity, and pain. The two greatest risk factors for OA are obesity and joint 
injury.1,2 Symptomatic OA is reported in 12% of American adults, with as many as 37% of adults 
demonstrating radiographic evidence of OA.3 OA is a growing problem due to aging population, 
obesity epidemic, and low intrinsic capacity for cartilage damage repair. Mesenchymal stem cells 
(MSCs) can present a novel paradigm to deal with the problem of tissue regeneration, cartilage 
damage, and OA. Their paracrine effect on surrounding tissue reduces inflammatory responses 
with MSCs providing regenerative cells to repair damaged cartilage.4 The goal of this article is to 
provide a review of the use of MSCs delivered directly to diarthrodial joints by intra-articular 
injections for orthopedic cartilage repair and symptom relief. 
Numerous non-pharmacologic and pharmacologic options are used for symptom management in 
OA, but none of these strategies can improve the structural damage that occurs with OA.5,6 
Current OA treatment recommendations by the American Association of Orthopedic Surgeons 
(AAOS) emphasize educational and physical therapy, the use of acetaminophen and NSAID 
drugs, and intra-articular corticosteroid injections.7 Their recommendations regarding the use of 
growth factor injections and/or platelet rich plasma (PRP) remain inconclusive.7 
Surgical management of OA involves different degrees of invasive procedures with total joint 
replacement being the most common and the most invasive. Less invasive methods such as 
autologous chondrocyte implantation (ACI) have data proven benefit but an inability to correct 
large osteochondral defects.8 Microfracture and arthroscopic debridement of tissue also offer 
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symptomatic benefit with success rates similar to other less invasive techniques like autologous 
matrix induced chondrogenesis (AMIC); however, microfracture and arthroscopic debridement 
may result in the formation of biomechanically inferior fibrocartilage.9 One main goal of newer 
treatment of OA is the delivery or induction of stem cells to produce true hyaline cartilage. 
The success seen using mesenchymal stem cell therapy is rooted in the ability of MSCs to 
differentiate into all mesodermal tissues, specifically cartilage, bone, ligament, and tendon.  They 
are also capable of modulating functions of T and B cells and secreting a variety of growth 
factors and cytokines like IL-10 and IL-12p40, which are anti-inflammatory in function.10–12 This 
paracrine mechanism is thought to be a major directing force to accelerate and direct tissue repair 
by host derived cells.13 MSCs are thought to suppress local immune response by producing 
cytokines and prostaglandin E2, inhibiting fibrosis, and further stimulating differentiation of 
stem cells.14,15 MSCs have also demonstrated homing ability, specifically incorporating into 
injured tissue and assisting the healing of native tissues.16 Preclinical evidence has shown that 
MSCs injected into animal models of naturally occurring OA, enzyme-induced OA, and post-
traumatic OA may help to regenerate cartilage lesions.17,18 The research using animal models and 
comparisons of scaffold vs non-scaffold stem cell application has also been well reviewed and 
detailed previously.17, 19–21 These features make MSCs an attractive strategy for OA management 
with MSC isolation and delivery being critical to clinical success. 
Traditionally, MSCs have been isolated from bone marrow, typically from the iliac crest.22 
Wakitani et al. were the first to demonstrate the regenerative use of MSCs for articular cartilage 
repair in humans by surgically implanting culture-expanded bone marrow MSCs.23 Bone 
marrow- mesenchymal stem cells (BM-MSCs) have been widely studied but carry the morbidity 
associated with donor site pain and infection. However, in the past decade, multiple sources 
including adipose tissue, synovium, periosteum, umbilical cord blood, and peripheral blood have 
also been studied. Key components in selection of an appropriate MSC source include the 
accessibility of the harvest tissue, stem cell population density, and ease of cell differentiation, 
making adipose-derived stem cells (ADSCs) very attractive.24–26 ADSCs have been demonstrated 
to have similar differentiation capacity and morphology to bone marrow derived cells.24 
Although the most chondrogenic and osteogenic source of MSCs is synovium, ADSCs have 
chondrogenic and osteogenic activity requiring minimal stimulation by growth factors and 
cytokines.27–29 Augmentation, especially with a co-injection of PRP, may be beneficial.30 
PRP is novel biologic scaffold that has been widely used as a MSC carrier. PRP is non- 
immunogenic, readily bio-absorbable, and easily prepared in a perioperative setting, and thus 
meets the major criteria as a MSC carrier.30 A double blind prospective multi-center trial by 
Mishra et al. in 2013 demonstrated clinically meaningful improvement in refractory tennis elbow 
treated with PRP.31  
Bone marrow culture expanded mesenchymal stem cells  
Bone marrow mesenchymal stem cells (BM-MSCs) are the best characterized MSCs and have 
osteogenic and chondrogenic potential that is greater than that of ADSCs.27 These MSCs are a 
reliable source for intra-articular injections and have not been shown to increase risk of 
48
Qureshi et al.: Mesenchymal Stem Cells for Osteoarthritis
Published by Marshall University's Joan C. Edwards School of Medicine, 2018
malignancy.32 The earliest reports of successful BM-MSC injection therapy came in 2006 when 
Centeno et al. described a case report of a male patient with a twenty year history of hip pain and 
a diagnosis of OA. The patient was treated with two intra-articular hip injections of augmented 
BM-MSC one month apart. BM-MSC concentrate was added to hyaluronic acid and a thrombin 
activated platelet scaffold. The first injection was estimated to contain < 100,000 BM-MSC and 
the second 300-400,000 BM-MSC. At the time of the second injection, the patient had no MRI 
evidence of improvement but reported clinical improvement. At eight weeks post-injection, 
evidence of increased joint space and neocortex formation over the area of previous subchondral 
cysts was reported. Walking distances and sitting tolerances improved two levels as compared 
with pre-injection scores.33 Additional case reports and case studies have been reported (Table 
1). 
Table 1. Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs) 
Author/ 
Journal 
Stud
y 
Type 
Outcom
es 
Patholo
gy 
Treatm
ent 
Addition
al 
Treatme
nt 
# 
Patie
nts 
Follo
w-Up 
Significant  
Results 
Centen
o et al. 
2006 
Pain 
Physici
an 
Case 
repo
rt 
Harris 
Hip 
Score 
Hip OA Two 
injectio
ns of 
BMSC: 
1-3x105 
cells 
HA and 
thrombi
n –
activate
d 
platelet 
scaffold 
1 4 & 8 
week
s 
MRI showed 
new neo-cortex 
at 8 weeks 
Centen
o et al. 
2008 
Pain 
Physici
an 
Case 
repo
rt 
VAS 
function
al rating 
index 
Knee 
OA 
Culture
d 
BMSC: 
22.5 x 
105 
cells 
Platelet 
lysate 
injection
s 
1 24 
week
s 
Decreased VAS, 
and increased 
cartilage & 
meniscus 
volume on MRI 
at 3 months 
Emade
din et 
al. 
2012 
Arch 
Iran 
Med 
Case 
serie
s 
VAS, 
WOMA
C, 
walking 
distance 
Knee 
OA 
Culture
d 
BMSC: 
24x108 
cells 
 6 1 year MRI with 
cartilage 
thickening at 6 
months 
Orozco 
et al. 
2013 
Transpl
ant-
ation 
Case 
serie
s 
VAS, 
WOMA
C 
Knee: 
Kellgre
n & 
Lawren
ce 
Grade 
3,4 
Culture
d 
BMSC: 
~40x10
8 
injected 
 12 1 year Significant 
improvement in 
VAS scores 
Lee et Case ICRS Knee: Injected HA 35 24 Improvement in 
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al. 
2012 
Ann 
Acad 
Med 
Singap
ore 
serie
s 
evaluati
on 
package, 
MRI 
full 
thickne
ss 
cartilag
e 
lesions 
vs. 
open-
implant
ed  
injection 
at weeks 
2, 4 
inject
ed 
35 
open 
mont
hs 
IKDC, Lysholm, 
VAS, and SF36 
in all treatment 
groups 
Davatc
hi et al. 
2011 
Int J 
Rheum 
Dis 
Case 
serie
s 
Walking 
time, 
VAS 
Knee 
OA 
Culture
d 
BMSC: 
8x107 
injected 
 4 6 
mont
hs 
Increased 
walking time, 
improvement in 
VAS 
Varam 
et al. 
2013 
J Indian 
Med 
Assoc 
RCT ADL 
evaluati
on, OA 
outcome
s score, 
VAS 
Knee 
OA 
BMSC 
injectio
ns 
followi
ng 
debride
ment 
 25 in 
each 
group 
6 
mont
hs 
Improved OAOS 
and VAS 
Wong 
et al. 
2013 
Arthros
copy  
RCT MOCA
RT, 
Lysholm
, Tegner, 
IKDC 
Knee 
OA 
BM-
MSC 
Micro-
fracture, 
high 
tibial 
osteoto
my 
28 in 
each 
group 
1 year Improved 
MOCART, 
Lysholm, 
Tegner, and 
IKDC 
Vangsn
ess et 
al. 
2014 
JBJS  
RCT MRI 
findings, 
VAS 
Knee 
OA 
BM-
MSC 
Medial 
menisce
ctomy 
55 
patien
ts in 
each 
group 
1 and 
2 
years 
Improved 
meniscal 
volume, 
improved VAS 
BMSC- Bone Marrow-Derived Stem Cells; OA- osteoarthritis; HA- hyaluronic acid; 
WOMAC- Western Ontario and McMaster University Osteoarthritis Index; ICRS- 
International Cartilage Repair Society; ADL- Activities of Daily Living; VAS- Visual Analog 
Scale; SF-36- Short Form Health Survey; MOCART- Magnetic Resonance Observation of 
Cartilage Repair Tissue 
 
In 2008, Centeno et al. published a case of knee OA treated with a single injection of cultured 
BM-MSCs (22.4 million) and a platelet lysate preparation.  The patient had follow-up injections 
of platelet lysate one and two weeks after the first injection. Excellent outcomes were reported 
with a decrease in visual analog score (VAS) by 95% and magnetic resonance imaging (MRI) 
evidence of increased cartilage volume at three months post injection.34 In 2011, a study by 
Davatchi et al. reported the results of four patients with knee OA who were injected with 8x106  
BM-MSCs and were evaluated one week after the injection and then monthly for one year.35 
Functional assessments were made by walking time to pain, stair climb number, and VAS. Three 
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of the four subjects reported an improvement in walking time and stair climb capacity, and a 24-
50% improvement in VAS.  No improvement was seen on x-ray at follow-up. In another study 
by Emadenin et al., 6 patients with knee OA were injected with 24 million cultured BM-MSCs 
with 12- month follow-up. Optimal results were seen at 6 months as evaluated by VAS, Western 
Ontario and McMaster University Osteoarthritis Index (WOMAC), and walking distances. 
Importantly, pain reduction and improvement in joint function were also noted but decreased at 
one year. Three of the six demonstrated increased thickening of the meniscus on MRI at six 
months follow-up.36 
In 2012, a study by Lee et al. examined the effects of injecting BM-MSCs for seventy non-
randomized patients less than 55 years of age with full thickness chondral lesions in a single 
compartment of the knee. Thirty-five patients received previously established treatment using 
arthroscopic microfracture and arthroscopic surgical implantation of MSC with periosteal flap 
coverage. The other thirty-five received the same arthroscopic microfracture followed by 
injection of 10 million BM-MSCs then 2ml hyaluronic acid (HA) in an outpatient clinic after 
surgery. Follow-up injections of HA (2ml) at two and four weeks were also administered. 
Subjects were followed for twenty-four months and evaluated using International Cartilage 
Repair Society (ICRS) injury evaluation package, Short Form Health Survey (SF-36), 
International Knee Documentation Committee (IKDC) subjective evaluation form, the Lysholm 
knee scale, and the Tegner activity level scale. A post-op MRI was also obtained. MRI results at 
one year showed neocartilage with good filling and significant reduction in underlying marrow 
edema.  Improvement was seen in all patients, but the injected group was reported to have 
superior results according to the IKDC and Lysholm scores. No difference was noted between 
the VAS and the SF-36 score between the groups. As a result of the excellent clinical outcomes, 
no second look arthroscopies were performed.37 
Varma et al. conducted a randomized controlled trial (RCT) utilizing BM-MSC with fifty 
patients with mild to moderate knee OA. Half were treated by injection of buffy coated BM-
MSC concentrate following arthroscopic debridement and compared to debridement alone. VAS 
and osteoarthritis outcome scores (OAOS) were evaluated at one, two, three, and six months 
follow-up. Significant improvement was seen at six months for the stem cell group in VAS (5.24 
vs 2.12) and OAOS scores (56.57 vs 79.28).38 
Wong et al. also conducted an RCT using BM-MSC injections at the time of microfracture and 
high tibial osteotomy (HTO) for twenty-eight patients, and compared these results to twenty-
eight patients randomized to receive no MSC injection.39 At one year follow-up, patients’ 
magnetic resonance observation of cartilage repair tissue (MOCART) scores were improved in 
the group receiving MSCs. Patients in this group also reported statistically significant 
improvement in Lysholm, Tegner, and IKDC scores. 
In 2013, a cohort of twelve patients with Kellgren and Lawrence grade II-IV knee OA was 
injected with 40 million cultured BM-MSCs and followed for twelve months. Evaluation by MRI 
T2 showed improvement in cartilage, as well as significant clinical improvement in functional 
scores and VAS.40. These studies clearly demonstrate that optimal dosing of MSC is not known 
with ranges from 100,000 to 40 million BM-MSCs used in the studies presented. 
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In 2014, Vangsness et al. published their results from an RCT using BM-MSCs versus placebo 
injections administered to fifty-five patients seven to ten days after a partial medial 
meniscectomy.41 Patients received injections of either 50x106 allogeneic BM-MSCs, 150x106 
MSCs, or a hyaluronic acid control. The authors found increased meniscal volume on MRI in 
both groups receiving MSCs, and significantly increased VAS score improvement at one and two 
years in the MSC groups compared to the control group. 
Adipose-Derived Mesenchymal Stem Cells (ADSCs) 
A critical difference in studies using ADSCs versus BM-MSCs is the near immediate injection of 
stem cells following harvest; readily available reservoirs include the buttock, abdominal, and  
infrapatellar fat pads.26,30,42–45 Thus, adipose tissue is ideal for same day harvest and injection, 
making it attractive for traumatic injury cases. Recent studies using ADSCs have covered a 
wider spectrum of chondral related pathologies, including OA of the hip and knee, osteonecrosis 
of the femoral head, and osteochondral lesions of the talus (Table 2). 
Table 2. Adipose-Derived Mesenchymal Stem Cells (ADSCs) 
Author/ 
Journal 
Stud
y 
Type 
Outcom
es 
Patholo
gy 
Treatme
nt 
Additio
nal 
Treatm
ent 
# 
Patie
nts 
Follo
w-Up 
Significant  
Results 
Pak et 
al. 
2013 
PLOS 
ONE 
Case 
serie
s 
Pain 
scale/ 
MRI 
evaluati
on 
Chondr
o-
malacia 
Concent
rated 
ADSCs: 
~16x106 
HA, 
PRP 
3 18 
mont
hs 
Improvement in 
subjective pain 
scores, and MRI 
with evidence of 
cartilage 
restoration 
Pak et 
al. 
2011 J 
Med 
Case 
Reports 
Case 
serie
s 
MRI, 
VAS, 
function
al rating 
index 
Hip 
osteo-
necrosi
s and 
knee 
OA 
Concent
rated 
ADSCs  
PRP, 
HA, 
CaCl2 
4 12 
week
s 
MRI with 
evidence of 
increased 
cartilage 
thickness 
Koh et 
al. 
2012  
Knee 
Case 
Cont
rol  
Lysholm 
score, 
Tegner, 
VAS 
Knee 
OA 
Concent
rated 
ADSCs 
PRP, 
arthro-
scopic 
debride
-ment 
25 
cases 
in 
each 
group 
12 
mont
hs 
No difference 
from control 
Koh et 
al. 
2013 
Arthro-
scopy 
Case 
Cont
rol 
MRI, 
VAS, 
WOMA
C 
Knee 
OA 
Concent
rated 
ADSCs 
Arthros
copic 
debride
ment, 
PRP 
18 2 
years 
Decrease in 
WOMAC at 2 
years, with 
improvement 
correlation with 
cell count 
injected 
Kim et Coh VAS Osteoc Concent Arthros 30 22 Improved mean 
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al. 
2013 
Am J 
Sports 
Med 
ort 
Stud
y 
AOFAS, 
Ankle-
Hindfoo
t scale, 
Roles & 
Maudsle
y, 
Tegner 
hondral 
talar 
lesion 
rated 
ADSCs 
copic 
marrow 
stimulat
ion 
ADS
C 
35 
contr
ol 
mont
hs 
VAS and 
AOFAS in 
ADSC group. 
Spasov
ski et 
al.  
J Gene 
Med 
Case 
serie
s 
VAS, 
KSS, 
radiogra
phs 
Knee 
OA 
0.5-
1.0x107 
ADSCs 
 9 
patien
ts 
18 
mont
hs 
Improved VAS 
and KSS 
ADSC- Adipose-Derived Stem Cells; OA- osteoarthritis; PRP- platelet rich plasma; HA- 
hyaluronic acid; WOMAC- Western Ontario and McMaster University Osteoarthritis Index; 
VAS- Visual Analog Scale; AOFAS- American Orthopaedic Foot and Ankle Society; KSS- 
Knee Society Score 
 
A case series published by Pak et al. in 2011 evaluated the safety and efficacy of concentrated 
ADSCs in four patients.43 Two patients had stage IV osteonecrosis of the femoral head and were 
given intra-articular injections of ADSC concentrate mixed with PRP, HA, and CaCl2. Subjects 
returned every week for follow-up injection of PRP and CaCl2 for a total of four injections. Two 
other subjects with OA of the knee were injected with ADSC, PRP, and CaCl2. They also had 
weekly injections of PRP and low dose dexamethasone for four weeks. Patients were seen in 
follow-up at three weeks and twelve weeks. Pre-procedure evaluations included VAS, MRI, and 
functional rating index. Repeat MRI at twelve weeks showed bone regeneration of the femoral 
heads and regeneration of the meniscus in the OA patients. This study suggests that ADSCs may 
be partially responsible for patients’ improvement. In 2013, the same group published another 
case series using ADSC intra-articular injections to treat chondromalacia patellae in three 
patients.42 Each was evaluated pre-procedurally with MRI and VAS pain assessment. Low 
abdominal liposuction was used to collect ADSC and cells were concentrated the same day as 
injection. Sixteen million concentrated ADSCs were injected into the retropatellar joint space 
with PRP and HA. All patients returned on day three, seven, fourteen, and twenty-eight for 
repeat injections of PRP and HA with the day fourteen injection including low dose 
dexamethasone. Patients were seen for follow-up at three months, when MRI demonstrated 
cartilage-like tissue regeneration, and subjects reported 80-90% pain improvement. However, it 
should be noted that despite these positive outcomes, there were discrepancies in the authors’ 
reported protocol that limit interpretation of this study. 
In 2012, Koh et al. published a therapeutic case series of twenty-five subjects to evaluate 
whether percutaneous injection of ADSCs from the infra-patellar fat pad could improve clinical 
outcomes for knee OA.30 Intra-articular injections of ADSCs (mean 1.9 million) in concert with 
PRP and arthroscopic debridement were compared to a matched control group without injections 
of stem cells. All patients had follow-up injections of PRP on day seven and fourteen. Pre- and 
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post- operative evaluations were performed using VAS, Lysholm, and Tegner scores, and all 
revealed greater total improvement when compared to the control group. Overall outcomes were 
similar for pain relief and functional improvement.  Patients in this study were further evaluated 
at two years by MRI, VAS, and scores for WOMAC and WORMS. Interestingly, an 
improvement of WOMAC scores, from 49.9 at 0-1 years to 30.3 at 1-2 years was observed. 
Possibly the most important finding from the group was the correlation between cell count at 
injection and patient outcomes. Notably, there was also a positive correlation between the dosage 
of ADSCs and improvement of pain, function, and MRI findings.44 
Another study assessing the effect of ADSCs included thirty study patients and thirty-five 
control patients with osteochondral (OCD) lesions of the talus. All patients were over fifty years 
of age. This study assessed the role of ADSCs in treating talar OCD lesions in conjunction with 
marrow stimulation vs. marrow stimulation alone. ADSCs were harvested from the butt pad the 
day prior to treatment. Outcomes were assessed using VAS, AOFAS score, Roles and Maudsley 
score, and Tegner activity scale over a mean of twenty-two months. Patient outcome scores 
improved in both groups, and the authors noted that patients with lesions larger than 109 mm2 or 
with subchondral cysts were likely to have superior outcomes when treated with ADSCs.45  
Recently, Spasovski et al. evaluated the clinical and radiographic outcomes of a single injection 
of ADSCs in nine patients with knee osteoarthritis. The authors used a concentration of 0.5-1.0 x 
107 cells. After eighteen months of follow-up, patients reported improvement in VAS and knee 
society score (KSS). Radiographs showed neither improvement nor progression of degenerative 
changes.46 
Peripheral Blood Stem Cells  
Peripheral blood progenitor cells (PBPCs) are easily obtained with both central and peripheral 
intravenous access and have been successfully used to treat international cartilage repair society 
(ICRS) grade III-IV chondral knee lesions. The case series by Saw et al. describes five subjects 
who were treated with arthroscopic subchondral drilling followed by five weekly injections of 
PBPCs mixed with HA.47 Second look arthroscopy demonstrated articular cartilage regeneration 
with histologic sections showing hyaline cartilage regeneration as the major component of the 
repaired tissue. The success of the case series prompted Saw et. al. to evaluate the treatment 
process of five weekly injections of PBPCs mixed with HA in an RCT of fity patients with ICRS 
grade III-IV lesions randomized to either 1) those treated with subchondral drilling and HA 
alone, and 2) those treated with drilling followed by PBPCs and HA (Table 3). Subjective IKDC 
scores and MRI evaluations were made pre- and post-operatively on all patients, and second look 
arthroscopy and biopsy at eighteen months were taken from sixteen patients in each group. There 
were no statistically significant differences in IKDC scores. However, statistically significant 
improvement was seen in both MRI findings and ICRS II scores in the control group. 
Furthermore, more type 2 collagen was identified in the intervention group, as compared to 
“limited to no” type 2 collagen in the control.48 
In another case study of five patients who failed conservative therapy for knee OA, arthroscopic 
micro drilling was performed in all patients with two subsequent IA injections of PBPCs with 
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growth factors and HA, repeated at days seven and fourteen. Outcomes evaluated WOMAC and 
knee injury and osteoarthritis outcome scores (KOO) at baseline, one, and six months along with 
biopsy. Significant improvements in WOMAC and KOO scores were noted in all patients at one 
and six months. Biopsy showed increased proteoglycan and glycosaminoglycan content which 
suggested hyaline cartilage formation (Table 3).49 PBPCs presents a less invasive alternative to 
traditional BM-MSC and ADSC harvest protocols. 
Table 3. Peripheral Blood Mesenchymal Stem Cells (PBSCs) 
Author/ 
Journal 
Stud
y 
Type 
Outcom
es 
Patholo
gy 
Additional 
Treatment 
# 
Patie
nts 
Follow-
Up 
Significant  Results 
Saw et 
al. 
2013 
Arthros
copy 
RCT IKDC 
scores, 
MRI, 
biopsy 
Knee 
chondra
l lesion 
HA, 
subchondral 
drilling 
25 in 
each 
group 
18 
months 
Increased amounts of 
Type II collagen in 
stem cell group 
Saw et 
al. 
2011 
Arthros
copy 
Case 
serie
s 
Second 
look 
arthrosc
opy, 
tissue 
biopsy 
ICRS 
grade 
3-4 
knee 
lesion 
Arthroscopi
c 
subchondral 
drilling, HA 
5 10-26 
months 
Biopsy evidence of 
hyaline cartilage 
formation 
Turajan
e et al 
2013. 
J Med 
Assoc 
Thai 
Case 
serie
s 
WOMA
C, KOO, 
biopsy 
Knee 
OA 
Arthroscopi
c 
subchondral 
drilling, 
HA, growth 
factor 
5 6 
months 
Biopsy with 
increased 
proteoglycans and 
glycosaminoglycans 
suggestive of hyaline 
cartilage 
PBSC- Peripheral blood stem cells; ; OA- osteoarthritis; HA- hyaluronic acid; WOMAC- 
Western Ontario and McMaster University Osteoarthritis Index; ICRS- International Cartilage 
Repair Society; IKDC- International Knee Documentation Committee; KOO- Knee Injury and 
Osteoarthritis Outcome Scores 
 
Discussion  
Review of current research involving IA injection of MSCs for various chondral-related 
pathologies is promising. The rising interest in cartilage regeneration is predictable considering 
the impact that a successful regenerative treatment would have on the field of orthopedics. 
However, our knowledge of the process is still in the preliminary stages. The vast majority of the 
publications on stem cell injection therapy are preclinical, but have shown great promise in 
animal models and RCTs.8,15,17,18,21 Studies included in this review demonstrate the diversity and 
limitations of current research, especially relatively short patient follow-up and the variability in 
dosing regimens and use of concomitant therapies. However, symptomatic benefit and evidence 
of improvement on advanced imaging were noted in many studies. 
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MSCs can be harvested from bone marrow, adipose tissue, synovium, peripheral blood, 
umbilical cord blood, muscle, skin, and periosteum; each donor has a variable capacity to 
produce cartilage and bone. Each of these sources also differs in the relative ease or morbidity 
associated with harvesting MSCs. Furthermore, the optimal number of stem cells injected is far 
from certain. Although the dose-dependent nature of cartilage regeneration is still unknown, 
there is some evidence of a dose-dependent effect.41,42 Of the groups reviewed, dosing varied 
significantly with upwards of 40 million to as few as 100,000 cells being used, making any 
comparison between study outcomes difficult. The proper dose for injection therapy is a key 
point that needs to be clarified with future research. Finally, although outside the scope of this 
paper, allogeneic BM-MSCs avoid the expensive and slow cell expansion process used in 
autologous harvest, but theoretically may cause host immune rejection; no adverse reactions 
were identified in an RCT by Vega et al. in 2015 examining 30 IA injections for knee OA.50 
Cellular and biochemical factors related to chondrogenesis are other key developing areas of 
research. Extensive in vitro work has been done showing the growing characteristics and 
behavior of ADSCs in recombinant BMP-2, TGF-β, PDGF and in various biologic scaffolds like 
PRP.28,51–53 New discoveries and better understanding of MSC processes will continue to fuel 
advancements in the field of chondral regeneration. 
Limitations of MSCs for the treatment of OA must also be considered. Long-term safety and 
efficacy of these therapies has not been proven. In a review by Peeters et al. of 844 injections 
with a mean follow-up of twenty-one months, the authors concluded that applications of cultured 
stem cells in joints appears safe.54 A follow-up study by Jo et al. in 2017 examined the two year 
outcomes of their eighteen patients with knee OA who had received AD-MSC injections, and 
found that the clinical outcomes for low- and medium-dose groups deteriorated one year after 
injections, while the high-dose group results plateaued.55 Furthermore, patients with severe OA 
have decreased proliferative capacity of patient-derived MSCs which, in addition to the burden 
of their advanced degeneration and deformity, limits the utility of these therapies in many 
patients.56 With longer follow-up and further studies, we will continue to gather data and identify 
potential complications regarding MSC therapies. 
Conclusion 
MSCs have potential to be a widely used modality in the next decade. New RCTs, case reports, 
and cohort studies demonstrate the potential use of MSCs in a variety of cartilage-related 
pathologies and therapies. Larger RCTs are needed to identify optimal cell sources, required cell 
counts for injection, cell processing methods, and ideal supplemental ingredients such as PRP, 
HA, and growth factors. 
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